BCMA CAR-T vs. stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your myeloma must be measurable (enough protein in blood or urine, or an abnormal free light chain test).
- Your myeloma cells must have the BCMA target on their surface (confirmed by a lab test).
- Your doctor must say you are healthy enough for a stem cell transplant.
- You must not have had prior treatment with BCMA-targeted therapy or CAR-T cells.
- You must not have plasma cell leukemia, amyloidosis, or myeloma that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.